Disposable Syringes Market Size and Share
Disposable Syringes Market Analysis by Mordor Intelligence
The disposable syringes market is currently valued at USD 17.27 billion in 2025 and is forecast to reach USD 24.56 billion by 2030, advancing at a 7.30% CAGR. Heightened enforcement of quality standards, rising biologics volumes, and faster adoption of home-based care are the primary forces behind this expansion. Tier-1 manufacturers are capturing new orders as health systems exit contracts with suppliers that failed to meet U.S. Food and Drug Administration quality requirements. At the same time, injectable GLP-1 therapeutics and other biologics are driving a sharp increase in premium pre-filled and safety formats, creating a wider value pool inside the disposable syringes market. A parallel shift toward patient self-administration of chronic therapies further lifts unit volumes, offsetting margin pressure linked to volatile resin prices and growing scrutiny of single-use plastics.
Key Report Takeaways
- By product type, conventional syringes led with 62.61% revenue share in 2024, while safety variants are projected to expand at a 7.98% CAGR through 2030.
- By application, therapeutic injections held 51.21% of disposable syringes market share in 2024, while blood specimen collection is forecast to grow at 7.88% CAGR to 2030.
- By end user, hospitals accounted for 48.72% of the disposable syringes market size in 2024, but the home healthcare channel is advancing at an 8.21% CAGR over 2025-2030.
- By material, plastic formats commanded 91.29% share of the disposable syringes market size in 2024, whereas glass versions are moving at a 7.92% CAGR.
- By geography, North America led with 39.91% revenue share in 2024 and Asia-Pacific is poised for the fastest 8.12% CAGR through 2030.
Global Disposable Syringes Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
NGO-led injection-safety campaigns accelerate emerging-market adoption | +1.2% | Africa, Asia-Pacific, Latin America | Medium term (2-4 years) |
Mandated transition to single-use devices to curb HIV & HBV | +0.8% | Global, with emphasis on emerging markets | Long term (≥ 4 years) |
Surge in biologics & GLP-1 injectable drugs | +1.8% | North America, Europe, Asia-Pacific | Short term (≤ 2 years) |
Pre-filled auto-injector boom creates premium syringe demand | +1.1% | North America, Europe | Medium term (2-4 years) |
US FDA quality alerts on China-made syringes pivot volume to Tier-1 producers | +0.9% | Global, concentrated in North America | Short term (≤ 2 years) |
3-D printed micro-mold tooling slashes cap-ex for mid-scale makers | +0.4% | Global manufacturing hubs | Long term (≥ 4 years) |
Source: Mordor Intelligence
NGO-led Injection-Safety Campaigns Accelerate Emerging-Market Adoption
Local capacity expansion supported by multilateral funding has reduced the 2.2 billion unit auto-disable syringe gap that once threatened immunization programs. Revital Healthcare, the first WHO-prequalified African producer, now targets output beyond 300 million units a year, cutting delivered costs 15-20% compared with imports [1]Gavi, "African-made auto-disable syringes are bolstering immunisation on the continent," gavi.org. Regional manufacturing hubs strengthen supply resilience during public-health emergencies and lower logistics expenses, positioning emerging markets to shift away from reused devices. The initiative demonstrates how directed grants can create lasting production ecosystems that widen the addressable disposable syringes market.
Mandated Transition to Single-Use Devices to Curb HIV & HBV
More than 16 billion injections are administered yearly in developing regions, and 40% still involve reused equipment. Regulators are introducing phased bans on re-sterilizable devices to reduce the estimated 1.3 million annual deaths tied to unsafe injections. Safety syringes with automatic retraction or needle shields are becoming the default specification despite a 15-25% price premium, as sterilization overheads often exceed acquisition costs. Global health systems also incur training expenses when switching device formats, creating sticky demand that favors suppliers with large safety portfolios. These mandates underpin long-term volume visibility for the disposable syringes market.
Surge in Biologics & GLP-1 Injectable Drugs
Pharmaceutical companies are investing billions to secure fill-finish capacity for high-growth biologics. Novo Nordisk is spending USD 4.1 billion on a North Carolina facility dedicated to GLP-1 agents, and similar projects across Europe and Asia aim to prevent future shortages. Biologics demand specialty syringes with tighter extractable-leachable profiles and higher viscosity tolerance, boosting adoption of glass barrels and advanced cyclic-olefin copolymers. As self-administration replaces clinic-based dosing, per-patient injection frequencies rise, further enlarging the disposable syringes market.
US FDA Quality Alerts on China-Made Syringes Pivot Volume to Tier-1 Producers
In 2024 the FDA issued multiple warning letters and import alerts after more than 4,000 device failures involving Chinese-sourced syringes [2]FDA, "Evaluating Plastic Syringes Made in China for Potential Device Failures: FDA Safety Communication," fda.gov. Hospital systems immediately redirected orders toward verified suppliers, triggering capacity expansions at domestic plants in Nebraska, Connecticut, and Georgia. Tier-1 producers command premium pricing because health providers now treat origin validation as a risk-mitigation cost rather than a negotiable attribute. The enforcement wave reinforces regulatory barriers that limit re-entry of non-compliant firms, consolidating demand inside the established upper tier of the disposable syringes market.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Up-front cost premium vs. sterilizable glass/steel devices | -0.7% | Cost-sensitive emerging markets | Medium term (2-4 years) |
Complex, country-specific regulatory filings | -0.5% | Global, varying by jurisdiction | Long term (≥ 4 years) |
Volatile polypropylene & cyclo-olefin polymer prices | -0.9% | Global manufacturing regions | Short term (≤ 2 years) |
Growing ESG pressure to cut single-use medical plastics | -0.6% | Europe, North America | Long term (≥ 4 years) |
Source: Mordor Intelligence
Up-front Cost Premium vs. Sterilizable Glass / Steel Devices
Glass syringes that survive 50-100 autoclave cycles cost USD 15-25 each, placing their per-use expense below USD 0.50 in high-volume programs. Disposable plastic units list at USD 0.15-0.35 but carry no reuse potential, forcing budget-constrained facilities to weigh capital efficiency against immediate liquidity. Where sterilization infrastructure exists, administrators sometimes favor reusable devices, slowing conversion momentum. Price sensitivity remains particularly acute in vaccination drives financed through public tenders that prioritize the lowest upfront bid, compressing growth for the disposable syringes market in those scenarios.
Growing ESG Pressure to Cut Single-Use Medical Plastics
Healthcare generates 5.9 million tons of waste each year, and single-use devices represent as much as one-quarter of that volume. Policymakers are calling for circular solutions, prompting evaluations of bio-based polymers and closed-loop collection pilots. Life-cycle analysis shows that well-designed plastic pre-filled injectors may outperform heavier glass alternatives on carbon and water metrics. Even so, suppliers must demonstrate credible waste-reduction roadmaps to avoid procurement penalties in regions that embed environmental scoring into tender criteria, introducing compliance costs that temper disposable syringes market expansion.
Segment Analysis
By Product Type: Safety Features Drive Premium Migration
Conventional devices still deliver scale efficiencies, but safety formats are growing faster and reshaping procurement preferences. In 2024 conventional variants held 62.61% of the disposable syringes market, yet safety models are tracking a 7.98% CAGR through 2030 as occupational-hazard prevention policies tighten. Retractable systems dominate the premium category because they minimize user steps and integrate smoothly into existing protocols. Facilities in North America and Europe now embed needle-stick injury metrics in value-based purchasing dashboards, accelerating contract shifts toward approved safety designs.
Manufacturers with domestic molding capacity also benefit from freight-cost differentials and tightened import controls. The transition from legacy glass barrels to cyclic-olefin polymers gives engineers more geometry options, improving ergonomic factors that influence nurse preference. With safety devices carrying 15-25% higher average selling prices, margin capture is sufficient to fund tooling upgrades. As a result, the disposable syringes market continues to experience a visible mix shift that tempers, but does not eliminate, the relevance of conventional lines.
Note: Segment shares of all individual segments available upon report purchase
By Application: Therapeutic Dominance Faces Diagnostic Growth
Therapeutic injections accounted for 51.21% of revenue in 2024 and remain the backbone of the disposable syringes market, powered by insulin, oncology, vaccine, and GLP-1 volumes. Self-administration pushes steady monthly throughput in community settings, while hospital wards favor compatible systems that integrate with closed-loop drug-dispensing cabinets. Premium biologic regimens frequently require low-dead-space or coated plungers to protect payload potency, translating into higher unit value.
Blood specimen collection, however, is registering a faster 7.88% CAGR and reshaping demand for thin-wall needles and vacuum-compatible barrels. Laboratory automation platforms rely on standardized dimensions, prompting manufacturers to guarantee tighter tolerances. Chronic disease monitoring protocols in aging populations add repeat sample draws that amplify syringe consumption. Even within emerging economies, expanded insurance coverage for diagnostic testing underpins incremental growth. Together these forces create a balanced outlook in which therapeutic supremacy coexists with a rising diagnostic contribution to disposable syringes market size.
By End User: Home Healthcare Disrupts Hospital Dominance
Hospitals made up 48.72% of revenue in 2024 as bulk-buying consortia negotiated national contracts and maintained centralized stores. Yet home healthcare is on course for the highest 8.21% CAGR, fueled by payers targeting lower admission rates through remote disease management. Patients managing diabetes or rheumatoid arthritis choose devices engineered for painless gliding and intuitive plunger resistance, supporting premium price points.
Pharmacy chains and mail-order distributors now bundle pre-filled pens and safety syringes with telehealth subscription plans, embedding recurring sales into care pathways. Packaging innovations such as color-coded caps and tamper-evident seals address caregiver concerns about dosing errors. As a result, the disposable syringes industry sees a revenue migration toward platform providers capable of integrating user coaching, refill reminders, and value-added consumables.

Note: Segment shares of all individual segments available upon report purchase
By Material: Plastic Dominance Challenged by Glass Premium
Plastic barrels commanded 91.29% of the disposable syringes market share in 2024, owing to low resin cost, high break resistance, and compatibility with fast-cycle molding. Rapid-clean hot-runner systems now approach 20 million shots before rebuild, keeping per-unit costs competitive despite polypropylene volatility. Copolymer advances also deliver glass-like clarity without the fracture risk that complicates logistics.
Even so, glass formats are advancing at a 7.92% CAGR because biologics often demand ultra-low extractable environments. SCHOTT Pharma’s polymer-glass hybrid products combine the inertness of borosilicate with weight savings, providing a mid-tier alternative [3]SCHOTT Pharma, "SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory," schott-pharma.com. Pharmaceutical firms deploying high-value injectables accept glass premiums as insurance against stability failures that could trigger batch recalls. Consequently, while plastics will remain the volume leader, glass captures a rising value slice within the disposable syringes market size.
Geography Analysis
North America held 39.91% of revenue in 2024 amid stringent enforcement actions that disqualified non-compliant imports and rewarded domestic plants with expedited inspections. BD’s multi-site program to add 485 million units of annual capacity anchors regional supply and shortens lead times during pandemic stockpile cycles. High healthcare expenditure levels support early adoption of auto-injector compatible safety syringes, and the local biologics pipeline guarantees sustained demand for glass and COC barrels. Harmonization between the new FDA Quality Management System Regulation and ISO 13485 reduces audit duplication, allowing manufacturers to reallocate quality-engineering resources toward product innovation.
Asia-Pacific is projected to post the fastest 8.12% CAGR through 2030 as India deploys Production Linked Incentives that cut import dependency from 70% to 50%. Domestic firms receive subsidies for clean-room upgrades and international partners gain duty concessions when setting up local molds, shrinking landed costs against entrenched suppliers. Rising chronic-disease incidence across Indonesia, Vietnam, and Thailand further expands baseline injection volumes, while aging demographics amplify requirements for routine diagnostics. The region also supplies pharmaceutical fill-finish services to global brands, creating export-linked demand spikes for specialty syringes.
Europe remains a mature but technology-driven arena where Medical Device Regulation compliance prompts systematic portfolio reviews. Manufacturers with dedicated post-market surveillance units are retaining market access, while smaller import-only firms struggle with clinical evaluation requirements. Sustainability directives add complexity as procurement officers favor bids demonstrating validated recycling pilots or lower life-cycle emissions. Gerresheimer’s newest plant in Georgia underscores a dual-continent strategy that balances European regulatory certainty with North American growth. Continued bio-similar market entry in Germany and France will reinforce steady, premium-segment consumption of disposable syringes.

Competitive Landscape
The disposable syringes market is fragmented. Cost leadership stems from in-house resin compounding, vertical integration of needle grinding, and extensive patent estates covering safety mechanisms. FDA import alerts against several low-cost exporters accelerated share gains for compliant producers that could immediately deploy surplus capacity.
Strategic partnerships are a defining theme. BD and Ypsomed integrate thin-wall glass barrels with 2.25 mL auto-injector systems to handle higher-viscosity drugs, while Gerresheimer works with biotech start-ups to co-develop micro-dosing syringes suitable for on-body pumps. Investment in 3D-printed micro-mold tooling cuts prototype cycles from 12 months to 4 months, enabling faster customization for unique biologic formulations. Intellectual-property barriers and device-drug combination filings further insulate incumbents from rapid share erosion.
Regional diversification continues as manufacturers hedge geopolitical risk. Terumo raised output in Vietnam to serve ASEAN tenders, and BD opened a second sterile-assembly line in Ireland linked to European pandemic reserves. Suppliers with global footprints can re-route finished inventory away from currency-depreciating markets, preserving margin stability. That capability is becoming a prerequisite for pharmaceutical partners seeking long-term supply agreements, reinforcing leadership positions inside the disposable syringes market.
Disposable Syringes Industry Leaders
-
Baxter International, Inc.
-
Becton, Dickinson and Company
-
Terumo Corporation
-
B. Braun SE
-
Gerresheimer AG
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- January 2025: BD announced an additional wave of investment in its U.S. manufacturing network to expand syringe, needle, and IV catheter capacity.
- July 2024: The U.S. Food and Drug Administration issued warning letters to Jiangsu Shenli Medical Production Co. and Jiangsu Hengrui Pharmaceuticals after inspections revealed significant CGMP violations in syringe production.
- March 2024: Hindustan Syringes & Medical Devices introduced Dispojekt single-use syringes in India.
- March 2024: BD accelerated U.S. output after the FDA cautioned against using plastic syringes sourced from select Chinese factories.
Global Disposable Syringes Market Report Scope
As per the scope of this report, disposable syringes refer to single-use syringes disposed of after single use. Disposable syringes eliminate the need for sterilization as they are intended for single-use, and commercial versions come pre-sterilized.
The disposable syringes market is segmented by type, end users, and geography. By type, the market is segmented into conventional syringes and safety syringes. By safety syringes, the market is segmented into retractable safety syringes and non-retractable safety syringes. By end user, the market is segmented into hospitals, diagnostic laboratories, and other end-users. The report offers the market size in value terms in USD for all the abovementioned segments.
By Product Type | Conventional Syringes | ||
Safety Syringes | Retractable | ||
Non-Retractable | |||
By Application | Therapeutic Injections | ||
Immunization | |||
Blood Specimen Collection | |||
Other Applications | |||
By End User | Hospitals | ||
Diagnostic Laboratories | |||
Home Healthcare Settings | |||
Other End Users | |||
By Material | Plastic | ||
Glass | |||
By Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Conventional Syringes | |
Safety Syringes | Retractable |
Non-Retractable |
Therapeutic Injections |
Immunization |
Blood Specimen Collection |
Other Applications |
Hospitals |
Diagnostic Laboratories |
Home Healthcare Settings |
Other End Users |
Plastic |
Glass |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia-Pacific | China |
Japan | |
India | |
Australia | |
South Korea | |
Rest of Asia pacific | |
Middle East and Africa | GCC |
South Africa | |
Rest of Middle East and Africa | |
South America | Brazil |
Argentina | |
Rest of South America |
Key Questions Answered in the Report
What is the current size of the disposable syringes market?
The disposable syringes market is valued at USD 17.27 billion in 2025 and is projected to grow to USD 24.56 billion by 2030.
Which product segment is expanding the fastest?
Safety syringes are advancing at a 7.98% CAGR through 2030 as regulators worldwide mandate single-use devices to prevent HIV and HBV transmission.
Why is Asia-Pacific expected to grow more quickly than other regions?
Government incentives for local manufacturing, combined with rising chronic-disease prevalence and healthcare infrastructure upgrades, underpin an 8.12% CAGR for Asia-Pacific.
How are ESG concerns affecting the disposable syringes market?
Sustainability mandates are pushing suppliers to develop recycling programs and bio-based polymers, adding compliance costs but also creating product-differentiation opportunities.
Which companies are leading the market?
BD, Terumo, Gerresheimer, SCHOTT Pharma, and Hindustan Syringes & Medical Devices together control about 60% of global revenue, reflecting moderate concentration.
What impact did FDA import alerts have on supply chains?
The alerts removed several low-cost Chinese producers from the U.S. market, prompting hospitals to shift orders to validated Tier-1 manufacturers and driving domestic capacity expansions.
Page last updated on: June 20, 2025